CJC-1295 vs Tesamorelin: A GHRH-Analogue Research Comparison
Quick verdict
CJC-1295 (without DAC) and Tesamorelin are both peptides (short chains of amino acids, the building blocks of proteins) that act like GHRH — a natural hormone that tells the body to release its own growth hormone in short bursts. They switch on the same target (the GHRH receptor), but they are built differently and last for different lengths of time. CJC-1295 is a short-acting copy of just the first 29 amino acids of GHRH, while Tesamorelin is a longer-lasting copy of the full 44-amino-acid GHRH. For research that needs a quick, sharp burst of growth hormone, CJC-1295 without DAC is the tool; for a longer-lasting, well-studied full-length version, Tesamorelin is. Both hit the same target, so researchers mostly use them as tools to compare within the somatotropic research category (“somatotropic” just means “to do with growth hormone”). These are research observations only, not therapeutic effects.
Overview: why these two are compared
CJC-1295 and Tesamorelin are the two most studied GHRH-like research peptides, so people compare them all the time. They reach the same goal — getting the pituitary (a small gland at the base of the brain) to release the body’s own growth hormone — but they start from different building blocks. The two things that set them apart are which part of GHRH they copy and how long they act. Both work one step before growth hormone by switching on the GHRH target, rather than adding growth hormone directly, so the gland keeps its own natural controls in research models. These are research observations only, not therapeutic effects.
Origin and structure
CJC-1295 without DAC — also called Modified GRF(1–29) — copies the first 29 amino acids of GHRH (the part that holds almost all of its power) and swaps in four amino acids that protect it from DPP-IV, an enzyme — a tiny molecular “scissors” in the blood — that would otherwise break it down. It is built to act for only a short time. See the full CJC-1295 research overview.
Tesamorelin copies the full 44-amino-acid human GHRH and adds a small chemical group (called trans-3-hexenoyl) to one end — its full chemical name is N-(trans-3-hexenoyl)-[Tyr¹]hGRF(1–44)NH₂. That added group shields it from the DPP-IV “scissors” and helps it last longer. See the full Tesamorelin research overview.
Mechanism: same receptor, different duration
Why it matters: both peptides switch on the exact same pathway, so the real research difference is the shape of the growth-hormone response — a quick burst versus a longer, steadier one.
Shared receptor cascade
Both CJC-1295 and Tesamorelin dock onto the GHRH receptor (the matching “lock” for these peptides) on somatotroph cells in the pituitary — the cells that make growth hormone. Docking there starts a chain of steps: it switches on an enzyme called adenylyl cyclase, raises a cell messenger called cAMP, and gets the cells to make and release growth hormone — which in turn raises IGF-1, a protein the body makes in response to growth hormone. The target and the steps are the same for both.
Duration and pulse shape
The difference is about timing. CJC-1295 without DAC acts for only about half an hour and is linked to a sharp, separate burst of growth hormone that looks like the body’s natural rhythm. Tesamorelin lasts longer, so it is a tool for studying a steadier, more drawn-out switching-on of the target. Researchers pick between them based on whether the study needs a quick burst or a longer exposure. These are research observations only, not therapeutic effects.
Side-by-side comparison
| Property | CJC-1295 (no DAC) | Tesamorelin |
|---|---|---|
| Based on | GHRH(1–29) fragment | Full GHRH(1–44) |
| Stabilisation | 4 amino-acid substitutions | trans-3-hexenoyl N-terminus |
| Duration of action | Short (~30 min) | Longer functional half-life |
| GH response | Sharp, pulse-like | More sustained |
| Receptor target | GHRH receptor | GHRH receptor |
| CAS / designation | Modified GRF(1-29) | 218949-48-5 |
Key research findings
Representative peer-reviewed studies for each compound, summarised for scientific reference only. Some are human clinical data, included for mechanistic context.
Characterised the GRF(1-29) analogue platform and confirmed activation of the pituitary GRF receptor.
PMID: 15817669
Reported that CJC-1295 restored normal growth in GHRH-deficient mice — functional GHRH-receptor agonism in an animal model.
PMID: 16822960
Characterised the pharmacology of the GHRH analogue now known as Tesamorelin (TH9507), establishing its non-clinical profile.
Which to study for which research question
Pick CJC-1295 without DAC when the study needs a quick, sharp burst of growth hormone, or when comparing the short no-DAC form against the longer-lasting DAC form.
Pick Tesamorelin when the study needs a longer-lasting, well-studied full-length GHRH-like peptide, or wants to follow growth hormone and IGF-1 over a longer stretch of time.
Both are available within the somatotropic research category and alongside the GH peptide research stack.
References & further reading
- Jetté L et al. “hGRF(1-29)-albumin bioconjugates activate the GRF receptor: identification of CJC-1295.” Endocrinology, 2005. PMID: 15817669
- Alba M et al. “Once-daily CJC-1295 normalizes growth in the GHRH knockout mouse.” 2006. PMID: 16822960
- Ferdinandi ES et al. “Non-clinical pharmacology and safety evaluation of TH9507 (Tesamorelin).” Basic & Clinical Pharmacology & Toxicology, 2007.
Summaries are paraphrased from the peer-reviewed literature. For full source citations, email veloxpeps@gmail.com.
